Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Rhea-AI Summary
Sight Sciences (Nasdaq: SGHT) will report fourth quarter and full year financial results for the period ended December 31, 2025 after market close on Wednesday, March 4, 2026.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET and a live webcast and archived replay will be available on the company's Investors page. The replay will be accessible for at least 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – SGHT
On the day this news was published, SGHT declined 1.68%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves (ARAY -8.47%, BSGM +39.91%, ELMD +6.6%, CVRX -3.85%, MGRM -1.64%) with no consistent sector direction tied to this scheduling update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Prelim 2025 results | Negative | -7.8% | Preliminary Q4 and 2025 revenue and cash usage details released. |
| Nov 11 | Clinical data update | Positive | +8.0% | Peer‑reviewed OMNI data showing IOP and medication reductions. |
| Nov 06 | Q3 2025 earnings | Positive | -0.6% | Q3 results with higher guidance and lower operating expenses. |
| Nov 06 | Leadership changes | Neutral | -0.6% | COO and CFO appointments plus board composition changes. |
Recent news has mostly seen price moves align with the perceived tone of announcements, though one positive earnings report coincided with a slight decline.
Over the last few months, Sight Sciences reported Q3 2025 results and raised full‑year revenue guidance on Nov 6, 2025, yet shares slipped modestly. Subsequent clinical publications on OMNI with TruSync technology around Nov 11, 2025 were followed by a notable price gain, highlighting the market’s focus on clinical validation. Preliminary Q4 and full‑year 2025 figures on Jan 13, 2026 led to a sharper decline. The current March 4, 2026 earnings date fits into this cadence of financial and clinical updates the market has been actively repricing.
Market Pulse Summary
This announcement schedules Sight Sciences’ Q4 and full-year 2025 report for March 4, 2026 and outlines access to the earnings call and webcast replay. In recent months, the stock reacted meaningfully to both preliminary financial data and clinical publications, underscoring the importance of upcoming detail on revenue trends, expenses, and cash. Investors may focus on how final audited results compare with January’s preliminary figures and on any updated commentary around growth drivers and profitability timelines.
AI-generated analysis. Not financial advice.
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2026 Sight Sciences. All rights reserved.
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
Media contact:
pr@SightSciences.com
FAQ
When will Sight Sciences (SGHT) report Q4 and full year 2025 results?
What time is the Sight Sciences (SGHT) conference call on March 4, 2026?
How can investors access the Sight Sciences (SGHT) live webcast and replay?
Will the Sight Sciences (SGHT) webcast be available for replay after the call?
What period do the March 4, 2026 results for Sight Sciences (SGHT) cover?
Will Sight Sciences (SGHT) provide guidance during the March 4, 2026 call?
